1. How I investigate chronic myelomonocytic leukemia
- Author
-
Daniel A. Arber, Attilio Orazi, and Valentina Fabiola Ilenia Sangiorgio
- Subjects
Oncology ,medicine.medical_specialty ,Myeloid ,Clinical Biochemistry ,Chronic myelomonocytic leukemia ,Disease ,030204 cardiovascular system & hematology ,World health ,03 medical and health sciences ,0302 clinical medicine ,Monocyte count ,Monocytosis ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Myeloproliferative neoplasm ,business.industry ,Biochemistry (medical) ,Leukemia, Myelomonocytic, Chronic ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,Peripheral blood ,medicine.anatomical_structure ,Mutation ,business ,030215 immunology - Abstract
The 2016 revised 4th edition of the World Health Organization classification of hematopoietic neoplasms updated the diagnostic criteria for chronic myelomonocytic leukemia (CMML). Persistent peripheral blood monocytosis of at least 1 × 109 /L and a percentage of monocytes ≥10% of the circulating white blood cell count (WBC) are both prerequisite criteria for this diagnosis. CMML represents the prototype of "overlapping" myeloid neoplasms with concurrent myeloproliferative and myelodysplastic features. However, clinical presentation is heterogeneous, with cases showing prevailing "dysplastic" features and others a predominant "proliferative" phenotype. Accounting for this diversity, two variants of CMML are recognized: "dysplastic" CMML defined by WBC
- Published
- 2019
- Full Text
- View/download PDF